Aurobindo Pharma gets USFDA nod for generic Droxidopa capsules

The approved product is a generic version of Lundbeck NA Ltd's Northera capsules.

Weekly Tactical Pick | Aurobindo Pharma

Valuation at a discount to peers, but significant scope for margin improvement

Buy Aurobindo Pharma; target of Rs 1100: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated February 11, 2021.

Buy Aurobindo Pharma; target of Rs 1165: ICICI Direct

ICICI Direct is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1165 in its research report dated February 11, 2021.

Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $380 million to $650-700 million in three years backed by new plants in the US and Vizag

Aurobindo Pharm Standalone December 2020 Net Sales at Rs 3,710.86 crore, up 10.92% Y-o-Y

Aurobindo Pharm Consolidated December 2020 Net Sales at Rs 6,364.91 crore, up 7.97% Y-o-Y

Aurobindo Pharma Q3 net profit zooms over 4-fold to Rs 2,946.32 crore

The company had posted a net profit of Rs 705.31 crore in the corresponding period of the previous fiscal, Aurobindo Pharma said in a filing to BSE.

Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.

Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1024 in its research report dated December 17, 2020.

COVID Vaccine: The opportunities for investors - Part I

Vaccine rollout will throw up opportunities not just for the domestic pharmaceutical and healthcare industry but also the logistics value chain, right from vaccine production, delivery, storage and then the actual immunisation

Aurobindo Pharma completes sale of Natrol LLC to New Mountain Capital

Earlier, Aurobindo Pharma Managing Director N Govindarajan had said that proceeds from Natrol’s divestiture will be used to reduce debt and other new strategic initiatives.

Accumulate Aurobindo Pharma; target of Rs 921: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 921 in its research report dated November 12, 2020.

Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated November 12, 2020.

Buy Aurobindo Pharma; target of Rs 980: Motilal Oswal

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 980 in its research report dated November 12, 2020.

Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

Sharekhan is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1024 in its research report dated November 12, 2020.

Aurobindo Pharma: Leaner balance sheet and cash flows are bright spots

Key positives for Aurobindo Pharma are sustained performance in the anti-retroviral category and the traction in the US business

Aurobindo Pharma says ready to manufacture COVID-19 vaccines for others

This will be in addition to its own efforts to develop a vaccine. The company said it is investing Rs 250-Rs 275 crore on a new facility to manufacture vaccines that would be ready by April. The facility will have the capacity to manufacture 400 - 450 million doses of vaccines.

Aurobindo Pharma shares up 4% after Q2 PAT rises 26% YoY

Consolidated revenue from operations grew by 15.8 percent year-on-year to Rs 6,483.3 crore with the US formulation business showing a 12.5 percent growth YoY at Rs 3,189.8 crore in Q2.

Aurobindo Pharma Q2 profit jumps 26% to Rs 805.6 crore; US business grows 12.5%

ARV revenue at Rs 502.7 crore increased 111.4 percent YoY and API revenue at Rs 829 crore rose 2.9 percent YoY for the quarter ended September 2020, the company said in its BSE filing.

Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.

Buy Aurobindo Pharma; target of Rs 1025: ICICI Direct

ICICI Direct is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1025 in its research report dated October 26, 2020.

Natrol sale marks a subtle shift in Aurobindo Pharma’s business strategy

The Natrol sale will help Aurobindo Pharma focus on the core generic drug and injectable businesses

Aurobindo Pharma share price rises 4% as subsidiary sells business assets

Jefferies served as the sole financial adviser and Sullivan & Cromwell LLP acted as legal counsel to Aurobindo.

Buy Aurobindo Pharma; target of Rs 1030: Motilal Oswal

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 1030 in its research report dated September 27, 2020.